Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 221

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 221
---
 commercialization Company of the Hebrew University of Jerusalem.

In November
2022, the Predecessor exercised its option and signed a license agreement with Yissum.

Under the
agreement, the Predecessor undertook to finance research at Professor Bernholtz Yehezkel’s laboratory, promote the development
of the products that result from the research, and maintain the patents that result from the research.

The Predecessor
currently has three projects under four different agreements with Yissum:

LV-100 –
Liposomal Nano-Mupirocin: A new antibiotic treatment aimed at combating resistant bacteria which is in pre-clinical studies phase. The
Predecessor is obligated to pay royalties at the rate of 3% of net sales. The Predecessor shall pay Yissum the following amounts in connection
with the achievement of the following milestones per each Product (each, a “Milestone”): (1) $150 upon first patient enrolled
in a Phase I Clinical Trial; (2) $300 upon first patient enrolled in a Phase II Clinical Trial; (3) $450 upon First patient enrolled
in a Phase III Clinical Trial and (4) $600 upon first commercial sale in either Europe or the US, the earlier to occur of the two.

LV-200 –
Liposomal Candesartan (also called ARB): A supportive treatment designed to improve existing cancer therapies by enhancing drug efficacy
and reducing toxicity and side effects which is in pre-clinical studies. The Predecessor undertook to finance the research program. Upon
completion of the research plan, the Company will be able to decide whether it wants to license the technology. If so, a licensing agreement
will be signed.

<div align='center'>F-31</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 10 – COMMITMENTS AND CONTINGENCIES (Cont.)

LV-400 –
A Liposomal Platform for Vaccine Development: This platform is intended for the development of new vaccines, such as those for COVID-19,
Zika, and West Nile virus.

The Predecessor
is obligated to pay royalties at the rate of 3% of net sales. The Predecessor shall pay Yissum the following amounts in connection with
the achievement of the following milestones per each Product (each, a “Milestone”): (1) $150